

Sofosbuvir-Velpatasvir versus Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis
POLARIS-3


SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Study Features

- **Design:** Open-label, randomized, phase 3 trial to compare efficacy of a fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) for 8 weeks versus sofosbuvir-velpatasvir (SOF-VEL) for 12 weeks in patients with HCV genotype 3 and cirrhosis who were DAA-naïve
- **Setting:** 84 sites in United States, Canada, New Zealand, Australia, France, Germany, and United Kingdom
- **Entry Criteria**
 - Age ≥ 18 years
 - Chronic HCV GT 3 with compensated cirrhosis
 - HCV RNA $\geq 10,000$ IU/mL at screening
 - No prior treatment with DAA; prior peginterferon plus ribavirin allowed
- **Primary End Point:** SVR12

SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Study Design



Abbreviations: SOF = sofosbuvir; VEL = velpatasvir; VOX = voxilaprevir

Drug Dosing

SOF-VEL-VOX (400/100/100 mg): fixed dose combination; one pill once daily

SOF-VEL (400/100 mg): fixed dose combination; one pill once daily

SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Baseline Characteristics

Baseline Characteristic	SOF-VEL-VOX x 8 weeks (n = 110)	SOF-VEL x 12 weeks (n = 109)
Age, mean (range)	54 (25-75)	55 (31-69)
Male, n (%)	74 (67)	100 (92)
White, n (%)	100 (91)	97 (89)
Cirrhosis Features		
Platelets <100 x 10 ³ /μL, n (%)	30 (29)	21 (19)
Mean FibroScan (range), kPa	23 (13-75)	22 (13-75)
Body mass index, mean, kg/m ² (range)	28 (20-50)	27 (18-46)
Mean HCV RNA, log ₁₀ IU/mL (range)	6.0 (1.6-7.6)	6.3 (4.1-7.5)
IL28B CC, n (%)	41 (37)	52 (48)

SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis


POLARIS-3: Baseline Characteristics

Information on Prior Treatment	SOF-VEL-VOX x 8 weeks (n = 110)	SOF-VEL x 12 weeks (n = 109)
Treatment-Naïve	75 (68)	77 (71)
Treatment-Experienced	35 (32)	32 (29)
Peginterferon + Ribavirin	31 (89)	30 (94)
Other	4 (11)	2 (6)
Most Recent Treatment Response		
Nonresponder	16 (46)	8 (25)
Relapse	16 (46)	20 (63)
Other	3 (9)	4 (13)

SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Results


POLARIS-3: Overall SVR12 by Treatment Arm



SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Results


POLARIS-3: Overall SVR12 by Treatment Arm



SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Results


POLARIS-3: SVR12 by Treatment Experience



SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Results

POLARIS-3: SVR12 by Baseline RAS



Y93H: 6 patients in SOF-VEL-VOX group and 4 in SOF-VEL group; all achieved SVR.

No treatment-emergent RASs in SOF-VEL-VOX group. Both virologic failures in SOF-VEL group had Y93H.

SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Adverse Events

Adverse Event (AE), n (%)	SOF-VEL-VOX x 8 weeks (n = 110)	SOF-VEL x 12 weeks (n = 109)
Discontinuation due to AE	0	1 (1)
Serious AE	2 (2)	3 (3)
Serious Related AE	0	0
Deaths	1 (1) [§]	0
Common AE		
Headache	27 (25)	32 (29)
Fatigue	28 (25)	31 (28)
Nausea	23 (21)	10 (9)
Diarrhea	17 (15)	5 (5)
Laboratory AEs (Grade 3-4)	14 (13)	9 (8)

SOF-VEL-VOX versus SOF-VEL in GT 3 and Cirrhosis

POLARIS-3: Conclusions

Conclusions: “In phase 3 trials of patients with HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients with HCV genotype 3 and cirrhosis. Mild gastrointestinal adverse events were associated with treatment regimens that included voxilaprevir.”

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



The contents in this presentation are those of the author(s) and do not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.